FDA Issues Draft Guidance on Impurity Standards for Antibiotics

The U.S. Food and Drug Administration has released a new draft guidance titled “Establishing Impurity Specifications for Antibiotics”, inviting industry feedback until June 22, 2026. The document aims to support applicants and marketing authorisation holders in defining and managing impurities in fermentative and semi-synthetic antibiotic products.

The guidance applies broadly to new drug applications (NDAs), abbreviated new drug applications (ANDAs), antibiotic active substances referenced in drug master files (DMFs), and over-the-counter (OTC) monograph drugs.

It outlines key expectations for identifying and listing impurities and degradation products, selecting appropriate analytical methods, and setting scientifically justified acceptance criteria. The draft also differentiates requirements across regulatory pathways, including sections relevant to NDAs under Sections 505(b)(1) and 505(b)(2), ANDAs under Section 505(j), and OTC drugs under Section 505G of the FD&C Act.

By clarifying impurity control strategies, the FDA aims to ensure consistent quality, safety, and regulatory alignment across antibiotic products.

04-05-2026